vs
艾伯维（ABBV）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是GENMAB A/S的18.0倍（$16.6B vs $925.0M）。GENMAB A/S净利率更高（36.3% vs 10.9%，领先25.4%）。GENMAB A/S同比增速更快（18.7% vs 10.0%）。艾伯维自由现金流更多（$4.9B vs $327.0M）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
ABBV vs GMAB — 直观对比
营收规模更大
ABBV
是对方的18.0倍
$925.0M
营收增速更快
GMAB
高出8.7%
10.0%
净利率更高
GMAB
高出25.4%
10.9%
自由现金流更多
ABBV
多$4.6B
$327.0M
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $925.0M |
| 净利润 | $1.8B | $336.0M |
| 毛利率 | 72.6% | 93.8% |
| 营业利润率 | 27.3% | 38.9% |
| 净利率 | 10.9% | 36.3% |
| 营收同比 | 10.0% | 18.7% |
| 净利润同比 | 8354.5% | 65.5% |
| 每股收益（稀释后） | $1.02 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVGMAB
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | — | ||
| Q2 25 | $15.4B | $925.0M | ||
| Q1 25 | $13.3B | — | ||
| Q4 24 | $15.1B | — | ||
| Q3 24 | $14.5B | — | ||
| Q2 24 | $14.5B | $779.0M | ||
| Q1 24 | $12.3B | — |
净利润ABBVGMAB
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $938.0M | $336.0M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $-22.0M | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.4B | $203.0M | ||
| Q1 24 | $1.4B | — |
毛利率ABBVGMAB
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | 93.8% | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | 96.4% | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVGMAB
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 31.7% | 38.9% | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 27.6% | 30.3% | ||
| Q1 24 | 22.7% | — |
净利率ABBVGMAB
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 6.1% | 36.3% | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 9.5% | 26.1% | ||
| Q1 24 | 11.1% | — |
每股收益（稀释后）ABBVGMAB
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.52 | $5.42 | ||
| Q1 25 | $0.72 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.88 | — | ||
| Q2 24 | $0.77 | $3.13 | ||
| Q1 24 | $0.77 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $1.3B |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $5.3B |
| 总资产 | $134.0B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVGMAB
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.5B | $1.3B | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $13.2B | $622.0M | ||
| Q1 24 | $18.1B | — |
总债务ABBVGMAB
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVGMAB
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | — | ||
| Q2 25 | $-183.0M | $5.3B | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $6.8B | $4.4B | ||
| Q1 24 | $8.0B | — |
总资产ABBVGMAB
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | — | ||
| Q2 25 | $137.2B | $6.5B | ||
| Q1 25 | $136.2B | — | ||
| Q4 24 | $135.2B | — | ||
| Q3 24 | $143.4B | — | ||
| Q2 24 | $141.9B | $5.6B | ||
| Q1 24 | $148.9B | — |
负债/权益比ABBVGMAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $327.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 35.4% |
| 资本支出强度资本支出/营收 | 2.0% | 2.4% |
| 现金转化率经营现金流/净利润 | 2.87× | 1.04× |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVGMAB
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.2B | $349.0M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | $438.0M | ||
| Q1 24 | $4.0B | — |
自由现金流ABBVGMAB
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | $327.0M | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | $430.0M | ||
| Q1 24 | $3.8B | — |
自由现金流率ABBVGMAB
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | 35.4% | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | 55.2% | ||
| Q1 24 | 31.3% | — |
资本支出强度ABBVGMAB
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | 2.4% | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | 1.0% | ||
| Q1 24 | 1.6% | — |
现金转化率ABBVGMAB
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | 1.04× | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | 2.16× | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
